Mental Process – Talk Bio

VC Funding Uptick in Back Half of 2025 Has Analysts Hopeful for 2026

1 week ago talkbio0Tagged 2026, AI-driven, Attitude, Funding, Investments, IPO, M&A activity, MassBio, rates, venture capital, Vital capacity, Window (physical object)

venture capital; VC funding; 2025 H2; 2026 outlook; biotech; MassBio; IPO window; M&A activity; interest rates; AI-driven investment

VC Funding Uptick in Back Half of 2025 Has Analysts Hopeful for 2026

1 week ago talkbio0Tagged 2026, AI-driven, Attitude, Funding, Investments, IPO, M&A activity, MassBio, rates, venture capital, Vital capacity, Window (physical object)

venture capital; VC funding; 2025 H2; 2026 outlook; biotech; MassBio; IPO window; M&A activity; interest rates; AI-driven investment

VC Funding Uptick in Back Half of 2025 Has Analysts Hopeful for 2026

1 week ago talkbio0Tagged 2026, AI-driven, Attitude, Funding, Investments, IPO, M&A activity, MassBio, rates, venture capital, Vital capacity, Window (physical object)

venture capital; VC funding; 2025 H2; 2026 outlook; biotech; MassBio; IPO window; M&A activity; interest rates; AI-driven investment

VC Funding Uptick in Back Half of 2025 Has Analysts Hopeful for 2026

1 week ago talkbio0Tagged 2026, AI-driven, Attitude, Funding, Investments, IPO, M&A activity, MassBio, rates, venture capital, Vital capacity, Window (physical object)

venture capital; VC funding; 2025 H2; 2026 outlook; biotech; MassBio; IPO window; M&A activity; interest rates; AI-driven investment

Variant Bio Launches Inference, the World’s First Agentic AI Genomic Drug Discovery Platform

1 week ago talkbio0Tagged agentic AI, AI Platform, genomic drug discovery, Inference, Variant Bio

Variant Bio; Inference; agentic AI; genomic drug discovery; AI platform

FDA Policy Tracker: 2025 Was a Year of Change

2 weeks ago talkbio0Tagged 2025, Drug Approval, Food Safety, GRAS Reform, Improvements, Mental Recall, Trump administration, United States Food and Drug Administration

FDA; 2025; Trump Administration; Food Safety; FSMA 204; GRAS Reform; Drug Approvals; Recall Improvements

No public results for “Take the Biopharma Sentiment Index” Q1 2026 yet

4 weeks ago talkbio0Tagged Attitude, Biological Science Disciplines, Biopharma, biopharma executives, Biopharma Sentiment Index, geopolitical risk, M&A activity, Q1 2026, Sentiment, Surveys

Biopharma Sentiment Index; Q1 2026; biopharma executives; life sciences sentiment; 2026 outlook; M&A activity; AI in biopharma; geopolitical risk; survey data

The Endpoints 100: Biotech CEOs are feeling more upbeat about the road ahead

1 month ago talkbio0Tagged Attitude, biopharma executives, CEOs, dealmaking, E100 survey, Endpoints, Industry, IPO, Market, Recovery - action, reorganization, Sentiment, Trump administration, United States Food and Drug Administration, Window (physical object)

Endpoints 100; E100 survey; biotech CEOs; biopharma executives; industry sentiment; market recovery; dealmaking; IPO window; Trump administration; FDA reorganization; tariffs; 2025 outlook

Recent news on Biopharma Sentiment Index (BPSI)

1 month ago talkbio0Tagged Attitude, Biopharma, Biopharma Sentiment Index, BPSI, drug development sentiment, Endpoints, investing, News [Publication Type], Pharma Industry, Sentiment

Biopharma Sentiment Index; BPSI; Endpoints News; biopharma sentiment survey; drug development sentiment; biotech investing sentiment; pharma industry outlook

OncoPrecision Announces Oral Presentation of ONC001, a First-in-Class CD64-Targeting ADC for Monocytic Leukemia, at the 67th ASH Annual Meeting

2 months ago talkbio0Tagged annual, Antibody-Drug Conjugates, Asymmetric Septal Hypertrophy, CD64-targeting ADC, Leukemia, Myelocytic, Acute, Leukemia, Myelomonocytic, Chronic, meeting, Monocytic leukemia, OncoPrecision, Resistance (Psychotherapeutic)

OncoPrecision; ONC001; CD64-targeting ADC; monocytic leukemia; acute myeloid leukemia; ASH Annual Meeting; antibody-drug conjugate; CMML; therapy resistance